# US 2025/0049952 A1 · Improved gene therapy constructs for the treatment of propionic acidemia caused by mutations in propionyl-coa carboxylase alpha

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0049952 A1
- Document ID: US20250049952A1
- Status: Published application
- Kind: A1
- Application number: 18/723,020
- Filed: 2022-12-29
- Published: 2025-02-13
- Earliest claimed: 2021-12-29
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services
- Inventors: Charles P. Venditti; Randy J. Chandler
- Web page: https://patentgrep.com/patent/US20250049952A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0083: {characterised by an aspect of the administration regime}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N 9/93: {Ligases (6)}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/86: Viral vectors
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Y 604/01003: Propionyl-CoA carboxylase (6.4.1.3)
- G01N 33/5023: {on expression patterns}
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14171: Demonstrated in vivo effect
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- C12N 2830/42: being an intron or intervening sequence for splicing and/or stability of RNA
- C12N 2830/48: regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- G01N 2333/9015: Ligases (6)
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Polynucleotide expression cassettes comprising synthetic polynucleotides encoding human propionyl-CoA carboxylase alpha (synPCCA) are described herein. Related recombinant expression vectors, recombinant adeno-associated viruses (rAAVs), and compositions are also described. Also described are methods of treating a disease or condition mediated by propionyl-CoA carboxylase, comprising administering to a subject in need thereof a therapeutic amount of any of the polynucleotide expression cassettes, recombinant expression vectors, rAAVs, or compositions.

## Claims

### Claim 1

A polynucleotide expression cassette comprising:
(a) synthetic propionyl-CoA carboxylase subunit a (PCCA) polynucleotide (synPCCA) selected from the group consisting of:
(i) a polynucleotide comprising the nucleic acid sequence of any one of SEQ ID NOs: 2-7; and
(ii) a polynucleotide comprising a nucleic acid sequence with at least 80% identity to the nucleic acid sequence of any one of SEQ ID NOs: 2-7 which encodes the polypeptide of SEQ ID NO:8 and has equivalent or greater expression in a host relative to expression of any one of SEQ ID NOs: 2-7 or SEQ ID NO:1, wherein the polynucleotide does not have the nucleic acid sequence of SEQ ID NO: 1; and
(b) any one or more of the following features:
(i) a 3′ inverted terminal repeat (3′ ITR) with a length greater than 135 base pairs (bp) and less than 145 bp;
(ii) fewer CpG dinucleotides as compared to a nucleic acid sequence of any one or more of SEQ ID NOs: 9-12 and 35-40; and
(iii) fewer restriction enzyme recognition sites as compared to a nucleic acid sequence of any one or more of SEQ ID NOs: 9-12 and 35-40.

### Claim 2 (depends on 1)

The polynucleotide expression cassette of claim 1, further comprising any one or more of the following features:
(i) a 5′ ITR nucleotide sequence at least 90% identical to nucleotides 1 to 130 of SEQ ID NO: 41;
(ii) a core elongation factor 1 alpha (EF1S) promoter nucleotide sequence at least 90% identical to nucleotides 131 to 361 of SEQ ID NO: 41;
(iii) an intron nucleotide sequence at least 90% identical to nucleotides 362 to 526 of SEQ ID NO: 41;
(iv) a hepatitis B post translation response element (HPRE) nucleotide sequence at least 90% identical to nucleotides 2714 to 3439 of SEQ ID NO: 41;
(v) a polyA nucleotide sequence at least 90% identical to nucleotides 3440 to 3664 of SEQ ID NO: 41; and
(vi) a 3′ ITR nucleotide sequence at least 90% identical to nucleotides 3665 to 3805 of SEQ ID NO: 41.

### Claim 3 (depends on 1)

The polynucleotide expression cassette of claim 1, further comprising all of the following features:
(i) a 5′ ITR nucleotide sequence at least 90% identical to nucleotides 1 to 130 of SEQ ID NO: 41;
(ii) a EF1S promoter nucleotide sequence at least 90% identical to nucleotides 131 to 361 of SEQ ID NO: 41;
(iii) an intron nucleotide sequence at least 90% identical to nucleotides 362 to 526 of SEQ ID NO: 41;
(iv) a HPRE nucleotide sequence at least 90% identical to nucleotides 2714 to 3439 of SEQ ID NO: 41;
(v) a polyA nucleotide sequence at least 90% identical to nucleotides 3440 to 3664 of SEQ ID NO: 41; and
(vi) a 3′ ITR nucleotide sequence at least 90% identical to nucleotides 3665 to 3805 of SEQ ID NO: 41.

### Claim 4 (depends on 1)

The polynucleotide expression cassette of claim 1, wherein the synPCCA polynucleotide comprises a synPCCA1 nucleotide sequence at least 90% identical to SEQ ID NO: 2.

### Claim 5 (depends on 1)

The polynucleotide expression cassette of claim 1, comprising any one or more of the following features:
(i) a 5′ ITR nucleotide sequence consisting of a nucleotide sequence at least 90% identical to nucleotides 1 to 130 of SEQ ID NO: 41;
(ii) a EF1S promoter nucleotide sequence consisting of a nucleotide sequence at least 90% identical to nucleotides 131 to 361 of SEQ ID NO: 41;
(iii) a intron nucleotide sequence consisting of a nucleotide sequence at least 90% identical to nucleotides 362 to 526 of SEQ ID NO: 41;
(iv) a HPRE nucleotide sequence consisting of a nucleotide sequence at least 90% identical to nucleotides 2714 to 3439 of SEQ ID NO: 41;
(v) a polyA nucleotide sequence consisting of a nucleotide sequence at least 90% identical to nucleotides 3440 to 3664 of SEQ ID NO: 41; and
(vi) a 3′ ITR nucleotide sequence consisting of a nucleotide sequence at least 90% identical to nucleotides 3665 to 3805 of SEQ ID NO: 41.

### Claim 6 (depends on 1)

The polynucleotide expression cassette of claim 1, comprising all of the following features:
(i) a 5′ ITR nucleotide sequence consisting of a nucleotide sequence at least 90% identical to nucleotides 1 to 130 of SEQ ID NO: 41;
(ii) a EF1S promoter nucleotide sequence consisting of a nucleotide sequence at least 90% identical to nucleotides 131 to 361 of SEQ ID NO: 41;
(iii) a intron nucleotide sequence consisting of a nucleotide sequence at least 90% identical to nucleotides 362 to 526 of SEQ ID NO: 41;
(iv) a HPRE nucleotide sequence consisting of a nucleotide sequence at least 90% identical to nucleotides 2714 to 3439 of SEQ ID NO: 41;
(v) a polyA nucleotide sequence consisting of a nucleotide sequence at least 90% identical to nucleotides 3440 to 3664 of SEQ ID NO: 41; and
(vi) a 3′ ITR nucleotide sequence consisting of a nucleotide sequence at least 90% identical to nucleotides 3665 to 3805 of SEQ ID NO: 41.

### Claim 7 (depends on 1)

The polynucleotide expression cassette of claim 1, wherein the synPCCA polynucleotide consists of a synPCCA1 nucleotide sequence at least 90% identical to SEQ ID NO: 2.

### Claim 8 (depends on 1)

The polynucleotide expression cassette of claim 1, comprising a nucleotide sequence at least 90% identical to SEQ ID NO: 41 or SEQ ID NO: 42.

### Claim 9 (depends on 1)

The polynucleotide expression cassette of claim 1, consisting of a nucleotide sequence at least 90% identical to the nucleotide sequence of SEQ ID NO: 41 or SEQ ID NO: 42.

### Claim 10 (depends on 1)

A recombinant expression vector comprising the polynucleotide expression cassette of claim 1.

### Claim 11 (depends on 10)

The recombinant expression vector of claim 10, wherein the vector is a recombinant adeno-associated virus (rAAV), wherein the rAAV comprises an AAV capsid and a vector genome packaged therein.

### Claim 12 (depends on 11)

The rAAV according to claim 11, wherein the vector is comprised of the structure in FIG. 15B.

### Claim 13 (depends on 11)

The rAAV according to claim 11, wherein the AAV capsid is from an AAV of serotype 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, rh 10, hu37 or Anc, or mutants thereof.

### Claim 14 (depends on 13)

The rAAV according to claim 13, wherein the AAV capsid is from an AAV of serotype 9.

### Claim 15 (depends on 1)

A composition comprising (a)(i) the polynucleotide expression cassette of claim 1 or (ii) a recombinant expression vector comprising the polynucleotide expression cassette of (i), and (b) a pharmaceutically acceptable carrier.

### Claim 16 (depends on 1)

A method for treating a disease or condition mediated by propionyl-CoA carboxylase in a subject, the method comprising administering (i) the polynucleotide expression cassette of claim 1, (ii) a recombinant expression vector comprising the polynucleotide expression cassette of (i, or (iii) a composition comprising (i) or (ii) and a pharmaceutically acceptable carrier to a subject, wherein the subject has a disease or condition mediated by propionyl-CoA carboxylase.

### Claim 17 (depends on 16)

The method of claim 16, wherein the disease or condition is propionic acidemia (PA).

### Claim 18 (depends on 16)

The method of claim 16, wherein the vector is an rAAV and is formulated for administration at a dose of 1×1011 to 1×1014 genome copies (GC)/kg.

### Claim 19 (depends on 16)

The method of claim 16, wherein the vector is an rAAV and is formulated for administration as a single dose of rAAV.

### Claim 20 (depends on 16)

The method of claim 16, wherein the vector is an rAAV and is formulated for administration as multiple doses of rAAV.

### Claim 21 (depends on 1)

An in vitro method comprising administering to a cell of a subject, or a population of cells of the subject, the polynucleotide expression cassette of claim 1, wherein the polynucleotide expression cassette is inserted into the cell of the subject, or the population of cells of the subject, via genome editing on the cell of the subject using a nuclease selected from the group of zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), the clustered regularly interspaced short palindromic repeats (CRISPR/cas system) and meganuclease re-engineered homing endonucleases on the cell from the subject, or the population of cells of the subject.

### Claim 22 (depends on 16)

The method of claim 16, wherein the polynucleotide expression cassette, recombinant expression vector, rAAV, or composition is formulated for subcutaneous, intramuscular, intradermal, intraperitoneal, or intravenous administration.

### Claim 23

A nucleic acid consisting of (a) a nucleotide sequence that is at least 12 but no more than 35 contiguous nucleotides of any one of SEQ ID NO: 2-7; (b) a nucleotide sequence that is at least 90% identical to at least 12 but no more than 35 contiguous nucleotides of any one of SEQ ID NO: 2-7; or (c) a nucleotide sequence that is complementary to (a) or (b).

### Claim 24 (depends on 23)

The nucleic acid of claim 23, further comprising a detectable label.

### Claim 25 (depends on 23)

A collection of nucleic acids comprising two or more of the nucleic acids of claim 23.

### Claim 26 (depends on 25)

The collection according to claim 25, wherein the two or more nucleic acids comprise two or more different nucleic acids.

### Claim 27 (depends on 23)

An in vitro method for detecting the expression of synPCCA nucleic acid by cells, the method comprising:
(a) contacting a sample comprising nucleic acid from the cells with the nucleic acid of claim 23 or a collection comprising two or more thereof, thereby forming a complex; and
(b) detecting the complex, wherein detection of the complex is indicative of the expression of synPCCA nucleic acid by the cells.

### Claim 28 (depends on 1, 27)

The method of claim 27, wherein the method is carried out prior to administering (i) the polynucleotide expression cassette of claim 1, (ii) a recombinant expression vector comprising the polynucleotide expression cassette of (i, or (iii) a composition comprising (i) or (ii) and a pharmaceutically acceptable carrier to a subject.

### Claim 29 (depends on 1, 27)

The method of claim 27, wherein the cells are from a subject that has been treated with (i) the polynucleotide expression cassette of the polynucleotide expression cassette of claim 1, (ii) a recombinant expression vector comprising the polynucleotide expression cassette of (i), or (iii) a composition comprising (i) or (ii) and a pharmaceutically acceptable carrier, and wherein detection of the complex is indicative of the expression of synPCCA nucleic acid by the cells of the subject.

### Claim 30 (depends on 27)

The method of claim 27, wherein the cells are heart cells or liver cells.

### Claim 31 (depends on 27)

The method of claim 27, wherein the cells are hepatocytes or cardiomyocytes.

### Claim 32 (depends on 27)

The method of claim 27, wherein the cells are cells of a cell line.

### Claim 33 (depends on 27)

The method of claim 27, wherein the cells are cells of a heart cell line or a liver cell line.

### Claim 34 (depends on 27)

The method of claim 27, wherein the cells are cells of a hepatocyte cell line or a cardiomyocyte cell line.

### Claim 35 (depends on 34)

The method of claim 34, wherein the cells are cells of a hepatocyte cell line which does not express one or both of endogenous PCCA mRNA and PCCA protein.

### Claim 36 (depends on 27)

The method of claim 27, further comprising quantifying the synPCCA nucleic acid expressed by the cells.

### Claim 37 (depends on 27)

The method of claim 27, further comprising quantifying the cells that express the synPCCA nucleic acid.
